267 related articles for article (PubMed ID: 26988624)
1. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
Angulo JC; Valpas A; Rejas J; Linden K; Kvasz M; Snedecor SJ
Clin Drug Investig; 2014 May; 34(5):297-307. PubMed ID: 24567280
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
[TBL] [Abstract][Full Text] [Related]
6. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
7. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?
Yamanishi Y; Yamanishi T; Tajima H; Ikeda S
Int J Urol; 2018 Oct; 25(10):863-870. PubMed ID: 30112772
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder.].
Arlandis-Guzmán S; Brenes-Bermúdez F; Jiménez-Cidre MA; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
Arch Esp Urol; 2018 Dec; 71(10):809-824. PubMed ID: 30560796
[TBL] [Abstract][Full Text] [Related]
10. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
11. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
12. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care].
Kolbin AS; Vilyum IA; Proskurin MA; Balykina YE
Urologiia; 2016 Feb; (1):32-39. PubMed ID: 28247701
[TBL] [Abstract][Full Text] [Related]
17. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.
Arlandis-Guzman S; Errando-Smet C; Trocio J; Arumi D; Rejas J
BMC Urol; 2011 May; 11():9. PubMed ID: 21599928
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
